Shots: 

• Statera to receive an initial $2M up front, 5% of the issued & outstanding Immune's stock along with an additional fee upon achievement of revenue-based milestones, new indications & royalties & other payments from Immune in return for Statera's rights to any product containing low-dose naltrexone
• The agreement will strengthen Statera’s financial position with the potential to produce significant non-dilutive cash flow to fund other programs & helps to advance new product for immune-related diseases
• The transaction will produce ~$400M in non-dilutive payments to Statera. Additonally, Statera’s naltrexone assets can boost the ability to fight against chronic, life‐threatening diseases

Ref: Globenewswire | Image: Statera